Harry Skip Kiil Sells 4,189 Shares of Medtronic (NYSE:MDT) Stock

Medtronic PLC (NYSE:MDT) EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares in the company, valued at $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Medtronic Stock Down 2.1%

Shares of MDT opened at $80.27 on Thursday. Medtronic PLC has a 12 month low of $73.31 and a 12 month high of $106.33. The firm’s 50 day moving average is $81.10 and its 200-day moving average is $91.60. The stock has a market capitalization of $103.06 billion, a PE ratio of 21.52, a P/E/G ratio of 2.00 and a beta of 0.58. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last announced its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, topping the consensus estimate of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.61%. The company had revenue of $9.81 billion for the quarter, compared to analysts’ expectations of $9.62 billion. During the same period last year, the firm earned $1.62 earnings per share. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Equities research analysts forecast that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be issued a dividend of $0.72 per share. This is a boost from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 annualized dividend and a dividend yield of 3.6%. The ex-dividend date of this dividend is Friday, June 26th. Medtronic’s payout ratio is 76.14%.

Analyst Ratings Changes

Several research analysts have recently commented on MDT shares. Wells Fargo & Company lowered their target price on shares of Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, June 4th. Citigroup reduced their price target on shares of Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. TD Cowen reiterated a “buy” rating and set a $119.00 price target on shares of Medtronic in a research report on Thursday, June 4th. The Goldman Sachs Group reduced their price target on shares of Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $118.00 price target on shares of Medtronic in a research report on Thursday, June 4th. Seventeen equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.00.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic received FDA clearance for an updated Nellcor pulse oximetry system, which should help its monitoring portfolio and improve performance across diverse patient groups. Medtronic gets FDA nod for updated pulse oximetry system
• Positive Sentiment: The company earned CE mark approval for its Stealth AXiS robotic platform in ENT surgery, expanding its reach in Europe and supporting future procedure volume. Medtronic earns CE mark for Stealth AXiS robot platform in ENT surgery
• Positive Sentiment: Investor sentiment toward healthcare has improved as money rotates out of tech and into defensive sectors, which can help MDT relative to the broader market. As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play
• Positive Sentiment: Recent commentary has highlighted Medtronic as attractively valued at about 14x forward earnings with a 3.5% dividend yield and steady fiscal 2027 guidance. Is Medtronic Stock a Buy at 14x Forward Earnings?
• Neutral Sentiment: Analysts remain broadly constructive, but some recent price-target cuts suggest expectations have been reset after the latest earnings update.
• Neutral Sentiment: MarketWatch noted Medtronic underperformed some peers despite gains, indicating investors are still favoring stronger near-term names in the sector. Medtronic PLC stock underperforms Tuesday when compared to competitors despite daily gains
• Negative Sentiment: EVP Harry Skip Kiil sold 4,189 shares, a transaction that can modestly weigh on sentiment even if it may be routine. Harry Skip Kiil insider transaction
• Negative Sentiment: Investors also appear focused on margin pressure risks from tariffs and mix shifts, which could limit upside despite steady growth. Is Medtronic Stock a Buy at 14x Forward Earnings?

Institutional Trading of Medtronic

Several large investors have recently made changes to their positions in MDT. Artisan Partners Limited Partnership lifted its holdings in shares of Medtronic by 2.6% during the third quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock worth $117,579,000 after purchasing an additional 31,314 shares during the period. CSM Advisors LLC lifted its holdings in shares of Medtronic by 13.2% during the third quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock worth $27,169,000 after purchasing an additional 33,167 shares during the period. SageView Advisory Group LLC lifted its holdings in shares of Medtronic by 164.8% during the third quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock worth $2,305,000 after purchasing an additional 15,062 shares during the period. Madison Asset Management LLC lifted its holdings in shares of Medtronic by 15.0% during the fourth quarter. Madison Asset Management LLC now owns 195,216 shares of the medical technology company’s stock worth $18,752,000 after purchasing an additional 25,527 shares during the period. Finally, Bleakley Financial Group LLC lifted its holdings in shares of Medtronic by 17.8% during the third quarter. Bleakley Financial Group LLC now owns 87,313 shares of the medical technology company’s stock worth $8,316,000 after purchasing an additional 13,177 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).